Evaluating efficacy of bacteriophage therapy against Staphylococcus aureus infections using a silkworm larval infection model

FEMS Microbiology Letters

Volumn 347, Issue 1, 2013, Pages 52-60

  Takemura Uchiyama, Iyo ^a   Uchiyama, Jumpei ^a   Kato, Shin ichiro ^b   Inoue, Tetsuyoshi ^c   Ujihara, Takako ^b   Ohara, Naoya ^c   Daibata, Masanori ^a   Matsuzaki, Shigenobu ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b KOCHI UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Bacteriophage therapy; Silkworm; Staphylococcus aureus

Indexed keywords

CAPSID PROTEIN;

ADVERSE OUTCOME; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; BACTERIOLYSIS; BACTERIOPHAGE; BACTERIOPHAGE S25 3; BACTERIOPHAGE THERAPY; BIOLOGICAL THERAPY; BOMBYX MORI; CLINICAL EFFECTIVENESS; FEMALE; LARVA; LETTER; LIFESPAN; MICROBIAL MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION;

ANIMALIA; BOMBYX MORI; MAMMALIA; MIRIDAE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGE TWORT;

BACTERIOPHAGE THERAPY; SILKWORM; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; BOMBYX; FEMALE; LARVA; MICE; MICE, INBRED ICR; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS;

EID: 84883779719     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/1574-6968.12220     Document Type: Letter

References (28)

1. Apidianakis Y & Rahme LG (2011) Drosophila melanogaster as a model for human intestinal infection and pathology. Dis Model Mech 4: 21-30.
2. Ewbank JJ & Zugasti O (2011) C. elegans: model host and tool for antimicrobial drug discovery. Dis Model Mech 4: 300-304.
3. Fernandes P (2006) Antibacterial discovery and development-the failure of success? Nat Biotechnol 24: 1497-1503.
4. Fujiyuki T, Imamura K, Hamamoto H & Sekimizu K (2010) Evaluation of therapeutic effects and pharmacokinetics of antibacterial chromogenic agents in a silkworm model of Staphylococcus aureus infection. Drug Discov Ther 4: 349-354.
5. Gill JJ, Sabour PM, Leslie KE & Griffiths MW (2006) Bovine whey proteins inhibit the interaction of Staphylococcus aureus and bacteriophage K. J Appl Microbiol 101: 377-386.
6. Gu J, Xu W, Lei L et al. (2011) LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 49: 111-117.
7. Hamamoto H, Kurokawa K, Kaito C, Kamura K, Manitra Razanajatovo I, Kusuhara H, Santa T & Sekimizu K (2004) Quantitative evaluation of the therapeutic effects of antibiotics using silkworms infected with human pathogenic microorganisms. Antimicrob Agents Chemother 48: 774-779.
8. Hamamoto H, Tonoike A, Narushima K, Horie R & Sekimizu K (2009) Silkworm as a model animal to evaluate drug candidate toxicity and metabolism. Comp Biochem Physiol C Toxicol Pharmacol 149: 334-339.
9. Heo YJ, Lee YR, Jung HH, Lee J, Ko G & Cho YH (2009) Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob Agents Chemother 53: 2469-2474.
10. Kaito C & Sekimizu K (2007) A silkworm model of pathogenic bacterial infection. Drug Discov Ther 1: 89-93.
11. Kaito C, Akimitsu N, Watanabe H & Sekimizu K (2002) Silkworm larvae as an animal model of bacterial infection pathogenic to humans. Microb Pathog 32: 183-190.
12. Klumpp J, Lavigne R, Loessner MJ & Ackermann HW (2010) The SPO1-related bacteriophages. Arch Virol 155: 1547-1561.
13. Kurokawa K, Kaito C & Sekimizu K (2007) Two-component signaling in the virulence of Staphylococcus aureus: a silkworm larvae-pathogenic agent infection model of virulence. Methods Enzymol 422: 233-244.
14. Kutateladze M & Adamia R (2010) Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 28: 591-595.
15. Lavigne R & Ceyssens PJ (2012) Family Myoviridae. Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses (King AM, Lefkowitz E, Adams MJ & Carstens EB, eds), pp. 46-62. Elsevier Academic Press, San Diego, CA.
16. Lavigne R & Kropinski AM (2012) Family Podoviridae. Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses (King AM, Lefkowitz E, Adams MJ & Carstens EB, eds), pp. 63-85. Elsevier Academic Press, San Diego, CA.
17. Matsuzaki S, Yasuda M, Nishikawa H et al. (2003) Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage φMR11. J Infect Dis 187: 613-624.
18. Powers JH (2004) Antimicrobial drug development-the past, the present, and the future. Clin Microbiol Infect 10(suppl 4): 23-31.
19. Pukatzki S, Kessin RH & Mekalanos JJ (2002) The human pathogen Pseudomonas aeruginosa utilizes conserved virulence pathways to infect the social amoeba Dictyostelium discoideum. P Natl Acad Sci USA 99: 3159-3164.
20. Rashel M, Uchiyama J, Ujihara T et al. (2007) Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage MR11. J Infect Dis 196: 1237-1247.
21. Ryan EM, Gorman SP, Donnelly RF & Gilmore BF (2011) Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol 63: 1253-1264.
22. Seed KD & Dennis JJ (2008) Development of Galleria mellonella as an alternative infection model for the Burkholderia cepacia complex. Infect Immun 76: 1267-1275.
23. Seed KD & Dennis JJ (2009) Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex. Antimicrob Agents Chemother 53: 2205-2208.
24. Shields P & Tsang AY (2006) Mannitol Salt Agar Plates Protocols. Protocols. American Society for Microbiology, Washington, DC. www.microbelibrary.org Accessed 10 September 2012.
25. Synnott AJ, Kuang Y, Kurimoto M, Yamamichi K, Iwano H & Tanji Y (2009) Isolation from sewage influent and characterization of novel Staphylococcus aureus bacteriophages with wide host ranges and potent lytic capabilities. Appl Environ Microbiol 75: 4483-4490.
26. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M & Bartlett JG (2006) Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42: 657-668.
27. Uchiyama J, Rashel M, Takemura I, Wakiguchi H & Matsuzaki S (2008) In silico and in vivo evaluation of bacteriophage φEF24C, a candidate for treatment of Enterococcus faecalis infections. Appl Environ Microbiol 74: 4149-4163.
28. Uchiyama J, Takemura I, Satoh M, Kato S, Ujihara T, Akechi K, Matsuzaki S & Daibata M (2011) Improved adsorption of an Enterococcus faecalis bacteriophage φEF24C with a spontaneous point mutation. PLoS ONE 6: e26648.